(Yicai) March 26 -- Shares of Hengrui Pharmaceuticals rose after the Chinese firm granted US-Canadian pharma giant Merck ...

We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher. In this article, we are ...

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous challenges plaguing the company resulted in the dilution of the stock ...

Regarding tariffs, Merck has adopted an in-region, for-region strategy, with a strong US footprint and over 20 plants, allowing flexibility in production to mitigate tariff impacts.

Hengrui Pharma signed the agreement with Merck (NYSE: MRK) — known as MSD outside of the United States and Canada — for HRS-5346, its investigational oral small molecule Lipoprotein (a), or Lp (a), ...

Merck (MRK) announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR compared to placebo in adults with ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

German life sciences and pharma company Merck KGaA (MRK: DE) today revealed it has exercised its option with China’s Abbisko ...

US pharma giant Merck & Co and China’s Jiangsu Hengrui Pharmaceuticals have entered into an exclusive license agreement for ...

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular ...

Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance over the past month tells a different story, declining ...